Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

January 18, 2022

Dal Bosco v. NRx Pharmaceuticals, Inc. et al

Track this case

Case Number:

1:22-cv-00066

Court:

Delaware

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Joshua D. Wolson

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 18, 2022

    Pharma Biz Lied About COVID-19 Drug's Prospects, Suit Says

    NRx Pharmaceuticals was slapped with a proposed investor class action Tuesday claiming the company lied about the potential for Zyesami to get emergency use authorization to treat COVID-19, resulting in a stock tumble after the Food and Drug Administration didn't approve the respiratory-failure drug.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login